Communication Dans Un Congrès Année : 2019

Nanomedicine as a therapeutic approach against severe malaria, a proof of concept

Résumé

In 2018, children aged under 5 years accounted for 61% of all malaria deaths. The treatment of severe malaria is a major challenge. The medical care of severe malaria requires parenteral administration of quinine or artemisinin (ART) derivatives. The use of ART is limited by its poor aqueous solubility, short half-life and high first-pass metabolism. However, nanomedicine has significantly optimized the therapeutic efficacy of many active ingredients: doxorubicine (Myocet®), mifamuride (Mepac®), cytarabine (DepoCyte®), verteporfin (Visudyne®) or paclitaxel (Abraxane®). In this context, we have formulated original nanoparticles prepared by nanoprecipitation of bioesterified cyclodextrins (gamma-CD substituted with C10 alkyl chains), yielding either nanospheres or nanoreservoirs. Both nanosystems could associate ART with a 95% drug recovery, corresponding to drug levels of 0.4 and 1.6 mg/mL for nanospheres and nanoreservoirs, respectively and exhibited sustained release profiles over 96 h (nanoreservoirs) and 240 h (nanospheres). AR-loaded nanoparticles inhibited the growth of cultured Plasmodium falciparum, both multiresistant K1 and susceptible 3D7 strains with IC50 values 2.8 and 7.0 ng/mL, close to those of a reference ART solution. The in vitro plasma protein adsorption and phagocytosis by macrophage cells triggered by CD-C10 particles significantly decreased when they were decorated with amphiphilic PEGylated molecules (PEG1500 stearate, DMPE-mPEG2000, polysorbate 80). The resulting nanosystems were non-hemolytic and showed stealth properties after intravenous injection in mice, the residence time of DMPE-mPEG2000-decorated nanospheres reaching 24 h. Significantly enhanced pharmacokinetic parameters were obtained in healthy rats using a single dose (1.5 mg/kg or 2 mg/kg) of intravenously injected ART-loaded nanoparticles. The geometric mean exposures in plasma (AUC0-t) exhibited 2.35 and 3.26-fold increases with ART-loaded nanoreservoirs and nanospheres, respectively. The plasma half-life increased 4.00 and 6.25-fold and the clearance decreased up to 2.5 and 4.72-fold. These systems thus provide significant advantages for the intravenous treatment of severe malaria. Further studies should aim at consolidating these results with in vivo efficacy studies.

Fichier non déposé

Dates et versions

hal-04789122 , version 1 (18-11-2024)

Identifiants

  • HAL Id : hal-04789122 , version 1

Citer

Denis Wouessidjewe, B.G.J Yameogo, Luc Choisnard, Jean-Luc Putaux, Adama Gansané, et al.. Nanomedicine as a therapeutic approach against severe malaria, a proof of concept. 1er Congrès de la Société Ouest Africaine de Pharmacie Galénique Industrielle, Nov 2019, Abidjan, Côte d’Ivoire. ⟨hal-04789122⟩
88 Consultations
0 Téléchargements

Partager

  • More